Wei Xu

发表

A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life

Lu Lu, S. Xia, Rui Wang, 2022, Viruses.

Neutralizing SARS-CoV-2 by dimeric side chain-to-side chain cross-linked ACE2 peptide mimetics.

Lu Lu, Lu Wang, Yuwei Zhang, 2022, Chemical communications.

A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile

Lu Lu, Rui Wang, Z. Cong, 2022, Pharmaceuticals.

A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern

Jie Zhou, Lu Lu, Shuwen Liu, 2022, Viruses.

Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines

Jie Zhou, Lu Lu, Zezhong Liu, 2022, Journal of Medical Virology.

A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern

J. Chan, K. Yuen, Jie Zhou, 2022, Viruses.

A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant

J. Chan, K. Yuen, Jie Zhou, 2022, Cell Research.

Chemically Modified Bovine β-Lactoglobulin as a Broad-Spectrum Influenza Virus Entry Inhibitor with the Potential to Combat Influenza Outbreaks

Lu Lu, Weihua Li, Zezhong Liu, 2022, Viruses.

A core epitope targeting antibody of SARS-CoV-2

Guisheng Zhong, Suwen Zhao, Lu Lu, 2022, Protein & cell.

Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein

Lu Lu, Suiyi Tan, Shuwen Liu, 2022, Journal of virology.

A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein

Lu Lu, Xingmin Sun, S. Xia, 2022, Cell discovery.

Inhibition of viral suppressor of RNAi proteins by designer peptides protects from enteroviral infection in vivo.

Y. Qiu, S. Curry, Yuan Fang, 2021, Immunity.

A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry

D. Qu, Qiliang Cai, Q. Ding, 2021, Nature Communications.

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

Lu Lu, Wei Xu, Shibo Jiang, 2020, Cellular & Molecular Immunology.

Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products

Jie-Li Hu, A. Huang, N. Tang, 2021, Signal Transduction and Targeted Therapy.

Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines

Jie Zhou, Lu Lu, Zezhong Liu, 2022, Journal of medical virology.

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

J. Chan, K. Yuen, Lu Lu, 2022, Cell Research.

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors

Lu Lu, S. Xia, Yun Zhu, 2023, Emerging microbes & infections.

A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells

Lu Lu, T. Ying, Yanling Wu, 2022, mBio.

A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo

Lu Lu, Q. Dai, Wanting Wang, 2023, Communications biology.

An HR2-Mimicking Sulfonyl-γ-AApeptide Is a Potent Pan-coronavirus Fusion Inhibitor with Strong Blood–Brain Barrier Permeability, Long Half-Life, and Promising Oral Bioavailability

Lu Lu, Xingmin Sun, Jianfeng Cai, 2023, ACS central science.

IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies

Lu Lu, S. Xia, Qian Wang, 2023, Biomolecules.

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen

Lu Lu, S. Xia, Yun Zhu, 2023, Emerging microbes & infections.

A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates

Jie Zhou, Lu Lu, Jinghe Huang, 2023, Proceedings of the National Academy of Sciences of the United States of America.

A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein

Lu Lu, Xingmin Sun, S. Xia, 2022, Cell Discovery.

Prime editor‐mediated functional reshaping of ACE2 prevents the entry of multiple human coronaviruses, including SARS‐CoV‐2 variants

W. Liu, Jia Wei, Jifang Li, 2023, MedComm.

Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD

Jie Zhou, Yun Zhu, Zezhong Liu, 2024, Cell reports. Medicine.

A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies

Jie Zhou, Lu Lu, Chao Wang, 2023, International journal of molecular sciences.

Repurposing Navitoclax to block SARS‐CoV‐2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein

A. Tuzikov, Lu Lu, A. Andrianov, 2023, Journal of medical virology.

Cross-reactive antibody response to Monkeypox virus surface proteins in a small proportion of individuals with and without Chinese smallpox vaccination history

T. Ying, Qiao Wang, Shibo Jiang, 2023, BMC Biology.